This 2021 review article explores the potential of methylene blue (MB) as a therapeutic agent for COVID-19, focusing on its mechanisms of action and clinical investigations. MB exhibits multiple antiviral and immunomodulatory properties: it can inhibit SARS-CoV-2 replication by interfering with the viral spike protein's binding to ACE2 receptors, disrupt
